NFE2 Truncation Mutants Protect Wild-Type NFE2 from ITCH-Dependent Degradation

Area of Science:

• Hematology
• Molecular Biology
• Cancer Research

Background:

• Myeloproliferative neoplasms (MPNs) are clonal hematopoietic disorders.
• Key driver mutations include JAK2, MPL, and CALR.
• Nuclear factor erythroid 2 (NFE2) is increasingly recognized as a critical factor in MPN development and progression.

Purpose of the Study:

• To elucidate the molecular mechanism by which NFE2 mutations contribute to leukemogenesis.
• To investigate the role of E3 ubiquitin ligase ITCH in regulating NFE2 stability and activity.

Main Methods:

• Utilized HEK-293T cells to study protein interactions and degradation pathways.
• Investigated the interaction between wild-type NFE2, a gain-of-function mutant (NFE2-226aa), and the E3 ubiquitin ligase ITCH.
• Assessed the impact of NFE2 mutations on NFE2 protein stability and degradation mediated by ITCH.

Main Results:

• Demonstrated that the E3 ubiquitin ligase ITCH mediates the proteasomal degradation of wild-type (wt) NFE2.
• Identified a gain-of-function NFE2 truncation mutant (NFE2-226aa) that interacts with ITCH but resists degradation.
• Showed that NFE2-226aa protects wt NFE2 from ITCH-dependent degradation, leading to enhanced NFE2 activity.

Conclusions:

• ITCH-mediated degradation is a key regulatory mechanism for wt NFE2.
• Gain-of-function NFE2 mutations can promote leukemogenesis by evading degradation and enhancing NFE2 activity.
• These findings provide novel insights into MPN pathogenesis and potential therapeutic targets.